A new in vitro study demonstrates that KPV, one of Annular’s peptide compounds, significantly reduces fat accumulation in liver cells exposed to oleic acid, a model for non-alcoholic fatty liver disease (NAFLD). The research shows KPV works by reducing oxidative stress and regulating key fat-production pathways, specifically targeting the PPAR gamma pathway that controls fatty acid synthesis. At 100 μg/mL concentration, KPV prevented liver cell damage and normalized fat metabolism without toxicity. This provides mechanistic evidence for KPV’s potential therapeutic role in treating hepatic steatosis, the early stage of NAFLD.
For your business
New research shows KPV directly targets the cellular mechanisms behind fatty liver disease, reducing both oxidative stress and abnormal fat accumulation in liver cells.